Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
December 2021
September 2021
-
Featured NewsFDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
-
Featured NewsNovartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients
-
Featured NewsNovartis receives FDA fast track designation for LNA043 in osteoarthritis of the knee